Archive for November 24th, 2008

Acetadote

Safety and Effectiveness of Acetadote for Acetaminophen Toxicity
Allyson J. Whyte, Thompson Kehrl, Daniel E. Brooks, Kenneth D. Katz, Devin Sokolowski
The Journal of Emergency Medicine – 21 November 2008 (10.1016/j.jemermed.2008.05.007)
 

Abstract 

Background: Acetaminophen (APAP) toxicity is commonly encountered in the Emergency Department. Until 2004, treatment consisted of either oral N-acetylcysteine (NAC) or filtered oral NAC administered intravenously (i.v.). Intravenous acetylcysteine (Acetadote) is a new Food and Drug Administration-approved i.v. formulation of acetylcysteine manufactured by Cumberland Pharmaceuticals in Nashville, Tennessee. Little post-marketing data exists on the effectiveness and safety of i.v. acetylcysteine.

Objectives: We evaluated the clinical presentations and outcomes of patients treated with i.v. acetylcysteine for APAP toxicity.

Methods: We performed a retrospective chart review of patients treated with i.v. acetylcysteine for APAP ingestion. The primary outcome measures were: adverse reactions to and effectiveness of i.v. acetylcysteine, as defined by elevation of transaminases, liver failure, renal failure, death, and hospital length of stay (LOS). Data collected included: comorbidities, allergies, intentionality, timing and dosing of i.v. acetylcysteine, hospital LOS, transaminases > 1000 IU/L, development of liver failure requiring transplant, development of renal failure requiring hemodialysis, death, and anaphylactoid reactions.

Results: Sixty-four patients met our study criteria. Overall, 16 (25%) patients developed transaminases > 1000 IU/L, 4 (6%) of them died and 2 (3%) received liver transplants. Of the 15 patients (23%) treated within 8 h, none died or developed liver or renal failure, and only 1 developed transient transaminase elevation > 1000 IU/L. In the patients treated outside of 8 h, the median LOS was 3 days, whereas the group treated within 8 h had a median LOS of only 1 day. Six (9%) patients developed anaphylactoid reactions, 2 of whom received the i.v. acetylcysteine bolus over 15 min. Five of these patients were treated pharmacologically and completed treatment, and one had treatment discontinued for undocumented reasons.

Conclusion: Intravenous acetylcysteine seemed to be a safe and effective formulation of N-acetylcysteine.

Depression Screening

Screening for Depression in Emergency Department Patients
David Hoyer, Elizabeth David
The Journal of Emergency Medicine – 21 November 2008 (10.1016/j.jemermed.2008.05.004)

Abstract

Background: Depression is a common disease, yet it is not commonly studied in the Emergency Medicine literature. Study Objectives: To evaluate the prevalence of emergency department (ED) patients who have the symptoms of depression. Design: This was a prospective observational study performed at two EDs over a 9-month period. Adult patients were screened for depression symptoms by Diagnostic and Statistical Manual of Mental Disorders, 4th edition criteria. Results: There were 505 patients screened from April through December, 2004. Of the 505 patients, 109 (21.6%) screened positive for the symptoms of depression. The prevalence of positive screens was similar at each ED. Conclusion: About 1 in 5 ED patients may be suffering with depression.

OMNI Postings of 11/24/08

On this date in 1957, Cleveland Browns’ fullback Jim Brown set a club record of 237 yards rushing in one game.  Whereupon, Lee Marvin  went back to see him in the locker room after the game and said,  “When you retire, kid, come and see me.  I’ve got a whole bunch of Nazis trapped in a cellar…”
But I digress…
ACC and AHA have just published a new set of performance measures covering key features of the treatment of patients with ST-elevation and non-ST-elevation myocardial infarction.  For example, one of the metrics that has been deleted is the initiation of beta-blockers upon arrival at the hospital.  One metric that has been added is the timeliness of reperfusion therapy in patients transferred for percutaneous coronary intervention.  A link to the full text is included.
This is an FDA medication alert.  Asians who are on phenytoin or fosphenytoin are at increased risk for developing a severe dermatological condition such as Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  It can also occur with carbazepine.  Not all Asians.  Just the ones who are positive for a particular human leukocyte antigen (HLA) allele, HLA-B*1502.  Apparently, this allele is peculiar to Asians.
The FDA has given its imprimatur on a new oral analgesic for moderate-to-severe pain (like a mother-in-law).  It’s called Tapentadol.  It acts in two ways, opioid (narcotic) and non-opioid. It affects the brain and body primarily by activating opioid receptors in the brain, spinal cord and gastrointestinal tract. In addition, Tapentadol inhibits the reuptake of the brain chemical norepinephrine which possibly has an analgesic effect.  It pretty much has the same side-effects as other narcotic medications.
This is a Chicago Tribune article on the ice slurry that when given IV will improve organ survival.  Experiments on a 110-pound swine in 2000 showed that the slurry dropped the temperature of the animal’s heart and brain more than 20 times faster than conventional, external cooling methods.
Ever hear of lipodermatosclerosis?  Here is a case of one.  If you say it to the patient three times real fast, you can bill an extra $100.00.
Good night,
Paul R.

FDA Approves New Drug to Alleviate Moderate to Severe Pain

FDA, 11/24/08

The U.S. Food and Drug Administration has approved Tapentadol hydrochloride, an immediate-release oral tablet for the relief of moderate to severe acute pain.

Tapentadol is a centrally-acting synthetic analgesic that is available in doses of 50 mg, 75 mg, or 100 mg.

“This approval offers health care professionals an additional choice for treating moderate to severe acute pain,” said John Jenkins, M.D., director of the office of new drugs in the FDA’s Center for Drug Evaluation and Research.

Tapentadol acts in two ways, opioid (narcotic) and non-opioid. It affects the brain and body primarily by activating opioid receptors in the brain, spinal cord and gastrointestinal tract. In addition, Tapentadol inhibits the reuptake of the brain chemical norepinephrine which possibly has an analgesic effect.

Acute pain is a symptom of many medical conditions and can significantly interfere with a person’s quality of life and general functioning. Opioids are considered safe and effective in selected patients but can cause dependence, abuse, and addiction. All patients treated with opioids require careful monitoring by their health care professional for signs of abuse and addiction, and to determine when opioid analgesics are no longer needed.

The most common side effects from Tapentadol are nausea, dizziness, vomiting, sleepiness, and headaches. The labeling for Tapentadol includes warnings about the risk of respiratory depression; addictive depressive effects on the central nervous system when taken with alcohol, other opioids, or illicit drugs; and abuse potential.

Tapentadol is manufactured by Johnson & Johnson, New Brunswick, N.J.

FDA Alert: Asians & Phenytoin Therapy

 

Information for Healthcare Professionals Phenytoin (marketed as Dilantin, Phenytek and generics) and Fosphenytoin Sodium (marketed as Cerebyx and generics)

FDA ALERT [11/24/08]: FDA is investigating new preliminary data regarding a potential increased risk of serious skin reactions including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) from phenytoin therapy in Asian patients positive for a particular human leukocyte antigen (HLA) allele, HLA-B*1502.  This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including Han Chinese, Filipinos, Malaysians, South Asian Indians, and Thais.   Because fosphenytoin is a prodrug and is converted to phenytoin after administration, any concern regarding this association is also applicable to fosphenytoin.  Phenytoin and fosphenytoin are used to control tonic-clonic (grand mal) and complex-partial seizures in epilepsy.A recent FDA Information for Healthcare Professionals sheet (12/12/2007) described an increased risk of SJS/TEN with another antiepileptic drug, carbamazepine, in Asian ancestry patients with the HLA-B*1502 allele. 

The FDA is working to identify additional information to evaluate the possible risk of SJS/TEN from phenytoin and fosphenytoin in patients with HLA-B*1502.  Until the evaluation is completed, healthcare providers who are considering the use of phenytoin or fosphenytoin should be aware of the risks and benefits described in the current prescribing information for this drug. 

Because this new data suggests a possible association between HLA-B*1502 and phenytoin or fosphenytoin-induced SJS/TEN, and because of the known association between phenytoin and SJS/TEN, healthcare providers should consider avoiding  phenytoin and fosphenytoin as alternatives for carbamazepine in patients who test positive for HLA-B*1502.

This information reflects FDA’s current analysis of data available to FDA concerning these drugs. FDA intends to update this sheet when additional information or analyses become available.

To report any unexpected adverse or serious events associated with the use of this drug, please contact the FDA MedWatch program and complete a form on line at http://www.fda.gov/medwatch/report/hcp.htm  or report by fax to 1-800-FDA-0178, by mail using the postage-paid address form provided on line, or by telephone to 1-800-FDA-1088.Information for Healthcare Professionals to Consider when Prescribing Phenytoin or Fosphenytoin:

  • Phenytoin is an antiepileptic drug with some structural similarity to another antiepileptic drug, carbamazepine. Labeling for carbamazepine was recently updated to reflect an increased risk of serious skin reactions, including SJS/TEN, in Asian patients who had recently started taking carbamazepine and who tested positive for HLA-B*1502.
  • It is estimated that 10-15% or more of patients may carry the HLA-B*1502 allele in parts of China, Thailand, Malaysia, Indonesia, the Philippines, and Taiwan.  South Asians, including Indians, appear to have an intermediate chance of having HLA-B*1502, averaging 2 to 4%, but it is higher in some groups.  HLA-B*1502 appears to be present at a low frequency (<1%) in Japan and Korea. 
  • New preliminary data suggests that phenytoin may carry a risk of serious skin reactions in some Asian patients who tested positive for HLA-B*1502, similar to the risk carried by carbamazepine. Because fosphenytoin is a prodrug and is converted to phenytoin after administration, any concern regarding this association with phenytoin is also applicable to fosphenytoin
  • The carbamazepine label now recommends that testing for HLA-B*1502 be performed prior to initiating carbamazepine therapy in patients with ancestry in populations in which the allele may be present.  In patients who test positive for the allele, carbamazepine should not be used unless the benefits clearly outweigh the risks.
  • Because these new data suggest a possible association between HLA-B*1502 and phenytoin-induced SJS, and because of the known association between phenytoin and SJS/TEN,  the FDA is advising that Healthcare Providers consider avoiding phenytoin as an alternative to carbamazepine in patients positive for HLA-B*1502.
  • The possible risk of SJS from phenytoin and fosphenytoin in patients with HLA-B*1502 is still being studied; however, there is not yet enough information to recommend testing for HLA-B *1502 in Asian patients for whom phenytoin treatment is contemplated. 
  • Of carbamazepine-treated patients who experience a serious skin reaction, over 90% have this reaction within the first few months of treatment.  Patients who have been taking carbamazepine for more than a few months, without developing skin reactions, are at low risk of developing this reaction.  Similarly, the risk for serious skin reaction with phenytoin therapy appears to be greatest in the first few months of therapy.

More information can be found in the FDA Information for Healthcare Professionals sheet posted on 12/12/2007, (http://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm).   

Information for Patients Taking Phenytoin or Fosphenytoin to Consider:

  • If you have been previously prescribed carbamazepine to control seizures, then you might have had a test for a gene or “allele”, called HLA-B*1502, that can help to predict whether you might be at risk for a serious skin reaction from the drug. Phenytoin and fosphenytoin may carry a similar risk of serious skin reactions in some Asian patients who test positive for HLA-B*1502.
  • Having HLA-B*1502 is not abnormal, and there is no other known risk from having the allele.
  • Uncontrolled seizures are a serious risk. You should not stop your seizure control medication without talking with your physician.  If you develop a skin rash while taking phenytoin, fosphenytoin, or carbamazepine, you should immediately contact your physician and receive advice before taking another dose of these medications.  You should talk with your physician if you have any questions about phenytoin, fosphenytoin, or carbamazepine and control of your seizures.

Data Summary

The following data are currently being analyzed by FDA regarding the risk of serious skin reactions, including SJS/TEN in Asian patients positive for HLA-B*1502 who are treated with phenytoin:

  • An article in the May 2008 issue of Epilepsia (Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population) reported that the HLA-B*1502 allele was found in 4 out of 4 patients with SJS associated with phenytoin treatment in a Thai population.  In contrast, the frequency of HLA-B*1502 in the phenytoin-tolerant control group was much lower (18%).  Based on that article, a preliminary estimate of the risk for SJS in Thai patients who are new users of phenytoin and are positive for HLA-B*1502 is approximately 3%.   This compares to a risk estimate at the same epilepsy treatment center of approximately 0.3% in all new phenytoin users.  A previous article in the May 2007 issue of Epilepsia (Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese) reported a single case of phenytoin-associated SJS in a Chinese patient in Hong Kong who was positive for HLA-B*1502. 

Because of these new data suggesting a possible association between HLA-B*1502 and phenytoin-induced SJS/TEN, and the known association between phenytoin and SJS/TEN, consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.
Patients should not stop their seizure control medication without talking with their health care providers.  Patients should be instructed to call their physician if skin rash develops.  Patients being treated with phenytoin or carbamazepine are advised to talk with their health care providers if they have questions about phenytoin or carbamazepine and control of their seizures, or if they have questions about being tested for HLA-B*1502. 

References
Locharernkul, C. et al. (2008) Carbamazepine and phenytoin induced Stevens – Johnson syndrome is associated with the HLAB*1502 allele in Thai population. Epilepsia, Early Online Publication July 14, 2008:1-5  DOI: 10.1111/j.1528-1167.2008.01719.x.
Man C.B.L. et al.   Association between HLA-B*1502 Allele and Antiepileptic Drug-Induced Cutaneous Reactions in Han Chinese. Epilepsia 2007; 48(5):1015-8

 

To report any unexpected adverse or serious events associated with the use of this drug, please contact the FDA MedWatch program and complete a form on line at http://www.fda.gov/medwatch/report/hcp.htm or report by fax to 1-800-FDA-0178, by mail using the postage-paid address form provided on line, or by telephone to 1-800-FDA-1088.

A complication of morbid obesity

A 17-year-old female was admitted to the hospital for the evaluation and treatment of acute cellulitis and deep vein thrombosis of the right lower extremity. The history of her problem began 11 days earlier when she awoke with pain in her right lower extremity between her ankle and calf. She also experienced an undocumented, subjective fever that day. The next morning, she noted some erythema and swelling, and she was taken to a local ED for evaluation. She was found to have a deep vein thrombosis in the right leg and admitted for treatment of this, as well as for presumed cellulitis, with coumadin (Warfarin, Bristol Myers Squibb) and a combination of antibiotics: vancomycin, gentamicin, levofloxacin and caspofungin (Cancidas, Merck). During the next 10 days, she had occasional low-grade fever and no improvement in the appearance of her leg. She had a bone scan that was normal, but magnetic resonance imaging of her lower extremity could not be performed because she was morbidly obese. She was then transferred to our facility for further management. Except for her coagulation studies and mild elevation of the inflammatory markers (CRP and ESR) the rest of her lab tests at the referring hospital were normal.

Her past medical history is complicated by morbid obesity, but otherwise, it is unremarkable. There has been no trauma and her immunizations are up to date. There are some social stressors with her parents, but the patient denies drug use or sexual activity.

1   1  

Examination revealed a female whose vital signs are normal, but who weighs more than 500 pounds. Her right lower extremity is markedly swollen with brawny edema, pain and erythema and skin breakdown with a serosanguineous discharge as shown in figures 1 through 3 with her left leg shown in figure 4.

Her lab tests on arrival included a normal complete blood count and metabolic profile. Her ESR = 49 and C-reactive protein = 67. All blood cultures and wound stains and cultures for bacteria, fungi and acid-fast organisms at the referring hospital and at our lab are negative.

1

A skin biopsy revealed “Full thickness inflammation with hyperplastic epidermis, papillary dermal edema, vascular proliferation typical of stasis throughout and dense scarring extending into the subcutaneous fat with some fat necrosis. Small foci of fibrin and some blood are present and there are macrophages with hemosiderin pigment. Gomori methenamine silver and tissue Gram stains are negative. An immunostain for HHV8 [human herpesvirus 8] is negative.”

Discussion

This turned out to be lipodermatosclerosis, confirmed by the skin biopsy. 

Lipodermatosclerosis is more common in females and in patients who are obese, and is a direct consequence of venous insufficiency of the lower extremities. The deep vein thrombosis (DVT) in this patient no doubt contributed to this problem developing.

Histological studies suggest that lipodermatosclerosis appears to be caused by damage to the venous walls of the lower extremities caused by elevated venous pressure. This results in an inflammatory response, which includes activated macrophages and results in the destruction of adipose tissue (panniculitis). This results in fat appearing in the extracellular matrix, which in turn, stimulates more macrophages and activates fibroblasts, maintaining a vicious cycle of worsening inflammation (Vignale R, Panucio A, Saralegui P, et al. Histological studies in LDS associated with venous hypertension. Medicina Cutánea. 2004;32:111-116). The clinical manifestations typically include induration of the soft tissue to the point of wood-like hardening, erythema and in many, an inverted coke bottle shape of the leg above the ankle. Although, this feature may not be seen in those who are obese.

The treatment of lipodermatosclerosis should be in cooperation with various consultants, such as a wound management team, which may include compression therapy and ultrasound therapy; a hematologist if there’s a DVT to help tend to with low molecular weight heparin; and the services of a vascular surgeon may be needed. But, most important, the patients need to resolve the underlying contributing factors, such as weight reduction and increased activity.

As with the case presented, many of these patients are thought to have cellulitis initially, and usually have been treated with a variety of antimicrobials before arriving at the correct diagnosis. The clues in this case were that there were no organisms identified by the numerous stains, cultures or through biopsy during the hospitalization, and no improvement on the various antimicrobials used. The appearance of cellulitis may be very similar (figure 5), but the swelling of cellulitis is not likely to be hard (brawny). Sometimes, soft-tissue infections may have an unusual appearance as shown in figures 6 and 7, a patient with erysipelas of the leg that included some blistering.

There should not be much confusion between lipodermatosclerosis and an infected pressure ulcer. With a pressure ulcer, the infection is likely to be draining through the sore with minimal erythema and swelling around the ulcer, as shown in figure 8, a patient with a deep, infected pressure ulcer, including underlying osteomyelitis. Yet the soft tissue around it is minimally involved. Also, it would be highly unlikely that a pressure ulcer would appear in the lower extremity in that location. There are no “pressure points” in that location.

Lastly, necrotizing fasciitis is a rapidly progressive, severe infection of the deep tissues that ultimately results in a necrosis of the deep tissue and the overlying skin as shown in figures 9 and 10 (before and after surgical debridement). It is frequently caused by group A streptococcal infection, and often associated with varicella. Clearly, this is not what the patient had.

Source:  Infectious Diseases in Children, 11/08

IV Slurpee

Chicago Trbune, 11/24/08 (http://www.chicagotribune.com/features/lifestyle/health/chi-talk-slurry-monnov24,0,5986124.story)

Ken Kasza chuckles right along with wisecrackers who keep comparing his potentially breakthrough medical work to a Slurpee.

There is a fundamental difference. Cherry, grape and cola-flavored slush promotes brain freeze. Kasza’s protective hypothermia may save lives.

“Some people make it sound like you could go to the 7-Eleven and buy it,” said Kasza, a senior engineer at Argonne National Laboratory near Lemont. “But there is a subtle difference, and that makes all the difference.”

The ice slurry system Kasza and a team from Argonne and the University of Chicago are developing can inject an ice and saline slush directly to organs, cooling those organs. Reducing an organ’s temperature lowers its demand for oxygen and reduces the speed with which it deteriorates during trauma. That buys critical, even life-saving, time for surgeons working on patients in emergencies.

Kasza’s team has figured out how to shrink ice and smooth its jagged edges, allowing it to flow almost as easily as water through a minuscule catheter.

Experiments on a 110-pound swine in 2000 showed that the slurry dropped the temperature of the animal’s heart and brain more than 20 times faster than conventional, external cooling methods. More recently, the team successfully cooled a swine’s kidney and is now working on the spine, Kasza said.

Humans may not be far behind. Clinical trials to cool human kidneys may begin in a year.

New performance measures issued for STEMI/NSTEMI

MedWire, 11/21/08 (http://www.medwire-news.md/38/79109/Cardiology/New_performance_measures_issued_for_STEMINSTEMI.html)

New performance measures issued for STEMI/NSTEMI
By Joanna Lyford
21 November 2008
Circulation 2008; Advance online publication
MedWire News: The American College of Cardiology (ACC) and the American Heart Association (AHA) have published a new set of performance measures covering key features of the treatment of patients with ST-elevation and non-ST-elevation myocardial infarction (STEMI/NSTEMI).

The report is an update of the 2006 edition and defines measures of important healthcare processes, such as specific treatments for STEMI/NSTEMI, as well as measures of care structures, outcomes, and efficiency.

The main aim of the document is to improve the quality of clinical care, say the authors, although the measures may also be used for external review or public reporting of provider performance. All metrics are categorized as either performance measures or test measures.

“By facilitating measurements of cardiovascular healthcare quality, ACC/AHA performance measurement sets may serve as vehicles to accelerate appropriate translation of scientific evidence into clinical practice,” write Harlan Krumholz (Yale University, New Haven, Connecticut) and fellow authors.

“These documents are intended to provide practitioners and institutions that deliver care with tools to measure the quality of their care and to identify opportunities for improvement.”

A new aspect of the 2008 document is the deletion of “beta-blockers on arrival in hospital” as a metric. The rationale for this change was the “increased complexity of decision-making and controversy about the magnitude of net benefit,” according to the authors.

The revised document now specifies “statin therapy at discharge” as opposed to the previous, broader category of “lipid-lowering therapy.” It also removes the requirement that low-density lipoprotein cholesterol is >100 mg/dl before such therapy is initiated.

The report also introduces several new performance measures, including metrics dealing with the evaluation of left ventricular systolic function, the timeliness of reperfusion therapy in patients transferred for percutaneous coronary intervention, and referral to cardiac rehabilitation programs.

The ACC/AHA report was developed in collaboration with the American Academy of Family Physicians and the American College of Emergency Physicians, and is endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine.

It is co-published in the Journal of the American College of Cardiology and the journal Circulation.

Full Text:  http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.108.191099v1

Diagnosing TIAs

http://www.medscape.com/viewarticle/583963_print

Neurologists are proposing 3 clinical features to help clinicians diagnose difficult-to-assess transient ischemic attacks (TIAs). In a study to be published in the December print issue of Cerebrovascular Diseases and published in the November 4 Online First issue, researchers report that only 40% of cases in the emergency department are true TIAs.

“There are not a lot of objective findings on which to base a diagnosis and this can be exceedingly challenging. Neurologists should be involved in the diagnosis,” lead author Shyam Prabhakaran, MD, MS, from Rush University Medical Center in Chicago, Illinois, told Medscape Neurology & Neurosurgery.

To help bridge this gap, Dr. Prabhakaran’s team developed a list of bedside clinical features designed to help clinicians in training, nonneurologists, and less experienced neurologists more accurately distinguish TIAs from nonischemic causes.

They identified 3 clinical characteristics:

  1. Gradual symptom onset.
  2. History of unexplained transient neurologic attacks.
  3. Presence of nonspecific symptoms.

 

“Speed of onset, we found, was the strongest indicator of a TIA,” Dr. Prabhakaran added in a news release. “I typically ask my patients if their symptoms came on like lightning — within seconds,” he said. “With other neurological problems that can mimic a TIA — migraines or seizures — for example, symptoms take more than a minute to manifest.”

The research team examined the records of 100 emergency department patients diagnosed with TIA and admitted for further evaluation.

After inpatient evaluation and review, final diagnoses were made by 2 neurologists. Of the 100 patients, 40 were confirmed to have TIA and 60 nonischemic transient neurologic attacks.

Table. Independent Predictors of Nonischemic Transient Neurologic Attacks

Characteristic Odds Ratio P Value

“These data imply that without expert neurologic evaluation, a significant overestimation of the true prevalence and incidence of TIA is likely,” the researchers write.

They also point to several limitations to their work, including the fact that it is a hospital-based study and is not generalizable to outpatient referral or a community setting. Also, because no gold standard exists to improve diagnostic accuracy for TIA, the final diagnosis can be questioned.

Still, investigators report that their 3 clinical features correctly classified 79% of study participants. These data may be useful in the education of clinicians and may help better triage patients in the emergency department, they note.

“It’s important not to miss a diagnosis of TIA as these can be harbingers of stroke and patients need to be treated,” Dr. Prabhakaran added. “But at the same time, we don’t want to overdiagnose TIAs either. Overdiagnosis subjects patients to the risks of unnecessary and potentially dangerous medications and tests and leaves their actual condition untreated or inadequately managed.”